Navigation Links
AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors,and In Vivo Results for a GHRH Antagonist at the AACR Annual,Meeting in Los Angeles

QUEBEC CITY, April 13, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global, pure play biopharmaceutical company focused on endocrine therapy and oncology, today announced that it will present two abstracts outlining first in vitro data on its PI3K inhibitors as well as in vivo data on its GHRH antagonist, JMR-132, which both may potentially provide new therapeutic approaches for the treatment of cancer. These abstracts will be presented at the American Association for Cancer Research (AACR) Annual Meeting, to be held April 14-18 at the Los Angeles Convention Center in Los Angeles, California.

    Selected abstracts for poster sessions in the Exhibit Hall:


    Monday, April 16, 8:00 a.m. - 12:00 p.m. (PT)

        - Abstract #2379 "New Generation of Anilino-Substituted

          Pyridopyrazine-Urea Derivatives Show Highly Selective PI3K-

          Inhibition". Irene Seipelt, Eckhard Claus, Tilman Schuster,

          Emmanuel Polymeropoulos, Michael Teifel, Eckhard Gunther.

          The abstract reviews, for the first time, results of a preclinical

          development program on a new generation of pyridopyrazine

          derivatives which clearly indicate that these drug candidates

          selectively inhibit PI3K and could be valuable for the treatment of

          cancer.


    Tuesday, April 17, 8:00 a.m. - 12:00 p.m. (PT)

        - Abstract #3568 "GHRH-Antagonist in Combination with Docetaxel

          Chemotherapy induces regression of MX-1 human experimental breast

          cancers". Joerg B. Engel, Andrew V. Schally, Jozseph Varga, Gabor

          Halmos, Stefan Buchholz.

          The abstract reviews results which demonstrate that GHRH

          antagonist, JMR-132, inhibits doxorubicin resistant in MX-1 human

          breast cancers and induces growth arrest or total regression when

          combined with docetaxel chemotherapy. Consequently, JMR-132 could

          provide a new therapeutic approach for t
he treatment of early and

          metastatic breast cancer.

Copies of these abstracts are currently available and can be viewed on-line through the AACR 2007 Meeting website at: http://www.abstractsonline.com/viewer/?mkey=%7BE3F4019C%2D0A43%2D4514%2D8F66%2DB86DC90CD935%7D

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global, pure play biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.

    News releases and additional information are available at

    www.aeternazentaris.com


    Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes", "anticipates", "intends", "plans", "expects", "estimates", "will," "may", "should", "approximately", and the negative or other variations of those terms or comparable terminology, are forward-looking statements. Such statements reflect management's current views, intentions, strategies and plans and are based on certain assumptions.

Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the ability of AEterna Zentaris to implement its business strategies, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of AEterna Zentaris to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.

CONTACT: Jenene Thomas, Senior Director, Investor Relations & CorporateCommunications, (418) 655-6420, ; PaulBurroughs, Media Relations, (418) 652-8525 ext. 406, jenene.thomas@aeternazentaris.com paul.burroughs@aeternazentaris.com

Ticker Symbol: (Toronto:AEZ.),(NASDAQ-NMS:AEZS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
2. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
3. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. The Past, Present and Future of HLA Typing
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 12, 2016 On Thursday, Feb. 11, 2016, ... St. David,s North Austin Medical Center successfully completed the ... Xi ® Surgical System with Trumpf Medical,s advanced ... Thiru Lakshman , M.D., colorectal surgeon at the Texas ... Integrated Table Motion technology, which seamlessly combines the da ...
(Date:2/12/2016)... , Feb. 12 2016  OMS Supply, a large ... medical practitioners, announced today the recent launching of their ... a variety of features that enhance the user experience ... supplies. --> --> ... fairly new company that started in early 2016, they ...
(Date:2/12/2016)... --> ... Global Clinical Trials Review, H2, 2015 provides an ... trials landscape along with top level data related ... & E7), Trial Status, Trial Phase, Sponsor Type ... involved and enlists all trials (Trial title, Phase, ...
Breaking Medicine Technology:
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... ... Infusion Nurses Society (INS) states that vein visualization technology should be used to ... healthcare facilities around the world, the INS Standards mandate the use of vein ...
(Date:2/12/2016)... ... February 12, 2016 , ... According to an article published February ... a significant portion of hernia repairs throughout the United States. Commenting on this article, ... notes that this trend has not only been expected, but it seems to be ...
(Date:2/12/2016)... , ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future ... , As Winston Churchill said, “Those who don’t learn from history are doomed ... to expect when they come knocking this year. But that takes time. , Take ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... announced that nominations have closed for the ISE Southeast Awards 2016. Finalists and ... announced at the ISE® Southeast Executive Forum and Awards Gala on March 15, ...
(Date:2/12/2016)... ... ... AssureVest Insurance Group, a locally owned insurance firm with offices serving Washington NC ... to purchase computers and software for Mrs. Harrison’s 2nd and 3rd grade special needs ... area and has more than 60 2nd and 3rd graders with learning disabilities. A ...
Breaking Medicine News(10 mins):